RNA N6-Methyladenosine Regulator-Mediated Methylation Modifications Pattern and Immune Infiltration Features in Glioblastoma

Yimin Pan†, Kai Xiao†, Yue Li, Yuzhe Li and Qing Liu*

Department of Neurosurgery in Xiangya Hospital, Central South University, Changsha, China

Glioblastoma (GBM) is a group of intracranial neoplasms with intra-tumoral heterogeneity. RNA N6-methyladenosine (m6A) methylation modification reportedly plays roles in immune response. The relationship between the m6A modification pattern and immune cell infiltration in GBM remains unknown. Utilizing expression data of GBM patients, we thoroughly explored the potential m6A modification pattern and m6A-related signatures based on 21 regulators. Thereafter, the m6A methylation modification-based prognostic assessment pipeline (MPAP) was constructed to quantitatively assess GBM patients’ clinical prognosis combining the Robustness and LASSO regression. Single-sample gene-set enrichment analysis (ssGSEA) was used to estimate the specific immune cell infiltration level. We identified two diverse clusters with diverse m6A modification characteristics. Based on differentially expressed genes (DEGs) within two clusters, m6A-related signatures were identified to establish the MPAP, which can be used to quantitatively forecast the prognosis of GBM patients. In addition, the relationship between 21 m6A regulators and specific immune cell infiltration was demonstrated in our study and the m6A regulator ELAVL1 was determined to play an important role in the anticancer response to PD-L1 therapy. Our findings indicated the relationship between m6A methylation modification patterns and tumor microenvironment immune cell infiltration, through which we could comprehensively understand resistance to multiple therapies in GBM, as well as accomplish precise risk stratification according to m6A-related signatures.

Keywords: glioblastoma, m6A, immune infiltration, immunotherapy, prognosis

INTRODUCTION

Glioblastoma (GBM) is the most common lethal neoplasm of the central nervous system, accounting for approximately half of primary brain tumors and almost 60% of all types of gliomas (1). Even after complete surgical removal combined with adjuvant therapy, for example radiotherapy, chemotherapy, and targeted therapy, its prognosis remains notably poor with an extremely low 5-year survival rate of approximately 5% (1–3). In addition, GBM patients and families suffer a heavy burden due to progressive neurological deficits and decreasing quality of life
Despite the killing effect of systemic therapy after complete resection, infiltrating cancer cells can often escape, resulting in tumor recurrence, progression, and even death (5). Recent advances in precision oncology, immunology, and other disciplines have uncovered multiple experimental therapies, such as immunotherapy, gene therapy, and novel drug-delivery technologies, which are emerging as powerful tools to solve the complicated GBM treatment difficulties, including low permeability of the blood-brain barrier, complex tumor signaling pathways, and the absence of specific biomarkers (6). Since multimodality therapy heralds promise in achieving durable and broad antitumor responses, it is urgent to establish a reliable tumor classification and prognosis model for cancer treatment strategy planning.

Represented by immune checkpoint inhibitors (ICIs), Chimeric Antigen Receptor T-Cell immunotherapy (CAR-T), cancer vaccines, and oncolytic viruses, immunotherapy produces sustained killing of cancer cells by activating the patients’ own immune system. Since these immunotherapies reportedly produce durable effects on several cancers, these methods have also been applied to primary intracranial malignancies, including newly diagnosed and recurrent glioblastoma (7, 8). The existence of the blood-brain barrier (BBB) and tumor microenvironment (TME) prevents the immune system’s continuous and effective response on intraparenchymal lesions, which limits the application on CNS tumors, resulting in only a specific subgroup of glioma patients benefitting from this treatment (9, 10). Recent studies regarding the tumor microenvironment have challenged the traditional cognition that tumor tissue is composed of pure tumor cells (11). It holds that the core tumor cells are surrounded by a complex microenvironment, which consists of multiple components, such as newborn blood vessels, multiple cell factors, extracellular matrix (ECM), fibroblasts, and immune cells. Immune cells infiltrating the TME were confirmed to be predictive to patients’ clinical outcomes and have a critical role on the immune response affecting the efficacy of immunotherapy, indicating that identifying the infiltrating pattern of immune cells in TME is of great significance to estimate the prognosis of GBM patients and assess the value of various therapies (12, 13).

Recently, it was reported that the epigenetic modification of RNA has a potential specific dependence with microenvironment infiltrating immune cells, suggesting that elucidating the epigenetic characteristics of GBM can provide a comprehensive basis for immunotherapy (14). Among over 150 RNA modifications, N6-methyladenosine (m^6^A) RNA methylation is the most dominant form of epigenetic regulation, occupying approximately 0.3% of total adenosine residues (15-17). Three types of distinct m^6^A regulatory factors called “writers”, “erasers”, and “readers”, respectively, dynamically regulate the process of RNA translation, degradation, and nuclear export by methyltransferases, demethylases, and binding proteins, separately (18). In total, 21 regulators participate in the m^6^A RNA methylation process, among which RBM15, ZC3H13, METTL3, METTL14, WTAP, and KIAA1429 represent the methyltransferases, while FTO and ALKBH5 catalyze the demethylation process. The remaining regulators, such as YTHDF1/2/3, are a group of RNA-binding proteins identifying specific m^6^A methylation regions to regulate downstream translation processes (19, 20). Although previous studies suggested YTHDF family have the role of enhancing translation, mRNA degradation, simultaneously accelerating translation and mRNA degradation respectively through binding different m^6^A-modified region (21-26), a novel model of YTHDF proteins shows that they bind the same mRNA and co-mediate mRNA degradation and cellular differentiation (27). A growing number of studies suggested that m^6^A regulators participate in multiple biological processes during tumor progression, thus elucidating the relationship between m^6^A regulators and tumor microenvironment infiltrating immune cells can assess GBM patients’ anticancer response to immunotherapy (28-30).

Traditional bulk sequencing provides genetic information at the resolution of individual samples, thus there is a limitation whereby it cannot identify specific cells in the given tissue. Hence, single-cell RNA sequencing (scRNA-seq) emerged as a practical tool to thoroughly distinguish each cell cluster, including immune cells in normal and tumor tissue (31). Due to the expensive sequencing costs, scRNA-seq cannot easily translate into clinical setting, and is primarily used for laboratory research only. In order to efficiently estimate immune cell infiltration level, we applied a relative quantitative algorithm based on single-sample gene-set analysis (ssGSEA), which can utilize traditional bulk expression profile data to determine the relative abundance of 23 immune cells in tumor tissue (32, 33). Additionally, by analyzing the correlation among expression patterns of 21 m^6^A methylation regulators, we established the m^6^A methylation-based prognostic assessment pipeline (MPAP) to calculate GBM patients’ m^6^A modification score (MMS). According to the MMS, we can further predict the clinical outcomes of GBM patients. Using the MPAP, we can determine m^6^A modification patterns in disease tissue by using only conventional bulk transcriptome data, which provides novel perspectives of GBM in an efficient and inexpensive way.

**MATERIALS AND METHODS**

**Patient Selection and Data Preprocessing**

From Gliovis (gliovis.bioinfo.cnio.es), a published data visualization web tool for brain tumor expression profile data uploaded on Gene-Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) (34), six glioblastoma datasets (Donson et al, n = 21; Ducray et al, n = 48; Gravendeel et al, n = 163; Kamoun et al, n = 19; Murat et al, n = 84; Rembrandt et al, n = 209); (tumor = 495; normal = 49) and corresponding clinical data were obtained for downstream analysis, which was sequenced using Affymetrix expression arrays (HG-U133_Plus_2, HG-U133A, HG_U95Av2, and HuGene-1.0-st). Before acquiring the expression data, the data had undergone robust multi-array average normalization, followed by quantile normalization using R package “affy.” The median of genes with multiple probe sets
was selected as the final expression value. To eliminate the batch effect produced not only by biological differences but by technical biases, we adopted the “Combat” function in the sva package based on the classical Bayesian algorithm. In addition, somatic datasets for glioblastoma and low-grade glioma were obtained from TCGA and Copy Number Variation (CNV) data was downloaded from the UCSC Xena website (https://xena.ucsc.edu/).

**M^6^A Regulators Clustering**

To further explore the regulation mode of m^6^A regulators, we extracted expression profiles of 21 m^6^A regulators from integrated GBM microarray datasets. Eight methylases (METTL3/14, RBM15/15B, WTAP, KIAA1429, CBLL1, ZC3H13), two demethylases (ALKBH5, FTO), and 11 RNA binding proteins (YTHDC1/2, YTHDF1/2/3, IGF2BP1, HNRNPA2B1, HNRNPC, FMR1, LRPPRC, ELAVL1) were included for unsupervised clustering analysis. Thereafter, we utilized the ConsensusClusterPlus package to run an unsupervised consensus clustering one thousand times to divide GBM patients into stable subgroups based on different m^6^A modification patterns (35). The R package of ConsensusClusterPlus was used to classify patients with qualitatively different m^6^A modification patterns based on the expression of 21 m^6^A regulators, and two distinct modification patterns were eventually identified using unsupervised clustering, including 233 cases in pattern A and 262 cases in pattern B. We termed these patterns as m^6^A cluster A-B, respectively. Additionally, we conducted a principle component analysis (PCA) of 21 regulators of GBM expression data to explore different m^6^A modification patterns between tumor and normal tissue, as well as each GBM cluster based on consensus clustering.

**Assessment of Immune Cell Infiltration**

To estimate immune cell infiltration level, we applied single-sample gene-set enrichment analysis (ssGSEA) using traditional microarray expression data (36). To identify multiple immune cells using ssGSEA, a specific gene set, including gene expression features of 23 immune cells, was employed (32, 33). We obtained an enrichment score for each sample, representing the relative infiltration level of immune cells, using ssGSEA.

**Gene Set Variation Analysis (GSVA) and GO/KEGG Annotation**

We downloaded KEGG pathway gene sets, named C2 collection, from the molecular signature database (MsigDB) (https://www.gSEA-msigdb.org/gsea/msigdb) for GSVA inputting. Next, we performed GSVA using R package “GSVA” on each subgroup to compare relative enrichment level of immune-related KEGG pathways (37). Furthermore, differentially expressed genes (DEGs) among subgroups of distinct m^6^A modification patterns were utilized for GO and KEGG enrichment analysis based on R package “ClusterProfiler”, which uses hypergeometric distribution tests to annotate DEGs (38).

**Differential Expression Analysis**

We performed a differential expression analysis among subgroups with different m^6^A modification patterns based on R package “limma”, which implemented an empirical Bayesian algorithm to identify DEGs (39). We considered genes with adjusted p values < 0.05 as statistically different DEGs and utilized these for downstream analysis.

**Collection of Expression Data Matching Immunotherapy Response Information**

In order to investigate potential predictive values of m^6^A modifications for immunotherapy response in GBM patients, we comprehensively searched expression data matching anticancer responses for PD-L1 treatment. A urothelial cancer cohort treated with anti-PD-L1 antibody was finally included for downstream analysis (40). The entire expression data and matching PD-L1 response information can be wholly obtained from R package IMvigor210CoreBiologies. For raw expression data in the R package, we adopted the function filterNvoom to normalize and filter out genes with low reads.

**Construction and Validation of MPAP**

Using DEGs obtained from subgroups with distinct m^6^A signatures, we aimed to construct a scoring system in order to estimate GBM patients’ prognosis. Firstly, R package rsurv, a modeling tool to produce numerous Cox models and then select the optimum one, was applied to filter the survival-related genes for the purpose of enhancing the robustness using cross-validation methods. Next, we utilized the least absolute shrinkage and selection operator (LASSO) regression, an efficient regression approach for high-dimensional data with large correlated covariates (41–43), to establish our m^6^A methylation-based immune cell infiltration assessment pipeline (MPAP). Combining Robustness and LASSO regression, we established a MPAP based on 13 genes and its correlation coefficients. Simultaneously, our MPAP was also validated in another GBM cohort. Then, in univariate and multivariate analysis, m^6^A modification scores (MMS) obtained from the MPAP were proven to be independent prognostic factors in both training and verification sets (Table 1, Figure 5).

**Statistical Analysis**

R software (version 3.6.0) was used for all statistical analysis and p-values < 0.05 were considered statistically significant. Robustness regression was conducted to select the optimum Cox model and LASSO regression was subsequently performed to construct a predictive model. Thereafter, we utilized the Kaplan-Meier (K-M) approach to establish survival curves and log-rank tests to calculate p-values between each group. To find the optimum cut-off value of each dataset, we adopted R package survminer, which examined the efficiency of all potential cut-off points. Applying receiver operating characteristic (ROC) curves, we estimated the specificity and sensitivity of the predictive model, which was implemented using R package pROC. Correlation coefficients among 21 m^6^A regulators were calculated using the Spearman correlation analysis and transformed by -log10. In the training set and validation set, we used multivariate analysis and calculated the hazard ratio...
TABLE 1 | Univariate cox proportional hazards analysis of clinical parameters and m6A risk score level of glioblastoma (GBM) patients in the training set and validation set.

| Variables                      | Univariate analysis |          |          |
|--------------------------------|---------------------|----------|----------|
|                                | Training set        | Validation set |
|                                | HR(95%CI)           | P-value  | HR(95%CI) | P-value  |
| Age group                      |                     |          |          |
| Younger vs old                 | 0.41(0.286-0.61)    |          | 1.24(0.87-1.76) | 0.217   |
| CIMP status                    | 1.63(0.96-2.78)     | 0.068    |          |          |
| Gender                         | 1.04(0.78-1.40)     | 0.784    | 0.91(0.63-1.32) | 0.642   |
| Subtype                        | NE+PE vs CL+ME      | 0.53(0.32-0.86) | 0.0103 |
| m6A risk group                 | Low vs High         | 0.437    |          |          |
| Radiotherapy                   |                     |          |          |
| Yes vs No                      |                     |          |          |
| Chemotherapy                   |                     |          |          |
| Yes vs No                      |                     |          |          |
| IDH status                     | Wildtype vs Mutant  | 1.76(1.45-2.13) | 0.003   |
| 1p19q status                   | Non vs Codel        |          |          |

Bold values are statistically significant.

RESULTS

Somatic Mutation Frequency Landscape of 21 m6A Methylation Regulators

In our research, a total of 21 m6A RNA methylation regulators was determined, including eight methyltransferases (writer), two demethylases (eraser), and 11 RNA binding proteins (reader). To illustrate the process by which we constructed the MPAP and what datasets were applied in our study, a schematic workflow was developed dividing the overall work into four steps broadly (Figure 1A). In Figure 1B, we summarized the somatic mutation frequency difference of 21 regulators between low-grade glioma (LGG) and GBM. In 21 regulators, IGF2BP1, RBM15B, YTHDF2, and FTO were significantly higher in GBM than LGG containing one writer (RBM15B), one eraser (FTO), and two readers (YTHDF2, IGF2BP1). Despite the non-significant statistical difference between LGG and GBM among the remaining 17 regulators, the somatic mutation frequency in GBM on m6A regulators was considered to be more than in LGG, due to the larger sample size of LGG (508) than GBM (495), except HNRNPC, FMR1, and WTAP, which demonstrated that the somatic mutation frequency of GBM patients among m6A regulators tended to be higher than that of LGG patients. This data implies that higher somatic mutation frequency of m6A regulators may contribute to the malignant degree of gliomas. The somatic mutation frequency of 21 m6A regulators was depicted in GBM samples. Totally, in 495 GBM samples, 41 obtained alterations accounting for 10.43%. IGF2BP1 displayed the highest mutation rate, while WTAP and HNRNPC did not display any mutation (Figure 1C). Next, we further demonstrated the co-occurrence of 21 regulators, among which YTHDC1/2 and ZC3H13, YTHDC1/2 and LRPPRC, YTHDC1/2 and YTHDF3, YTHDC1 and YTHDC2, YTHDF3 and ZC3H13, YTHDF3 and LRPPRC, YTHDF2 and FMR1, and YTHDC2 and METTL14 exhibited significant correlation (Figure 1D). The compression of 495 GBM samples’ base conversion is shown in Figure 1E. Additionally, based on the transcriptome expression level of 21 m6A regulators, GBM samples can be entirely discriminated against normal tissue using PCA analysis (Supplemental Figure 1).

Expression Pattern Based on 21 m6A Methylation Modification Regulators

To explore m6A modification patterns in GBM, we included several GEO datasets and matching clinical information for integrative analysis. Applying copy number variation (CNV) alteration analysis, we observed widespread CNV alteration on 21 regulators, among which amplification and deletion vary. CBLL1, HNRNPA2B1, ELAVL1, and YTHDF1 displayed the prevalent CNV amplification, while ZC3H13, HNRNPC, METTL3, and WTAP displayed the opposite (Figure 2A). We further analyzed the transcriptome expression level of 21 m6A regulators in GBM patients. Results indicate that regulators with CNV amplification tend to exhibit higher mRNA expression levels compared to normal tissue in GBM patients, and vice versa, suggesting that the expression levels of m6A regulators are predominantly influenced by CNV alterations (Figure 2B). Nevertheless, the transcriptome expression level of some specific regulators including HNRNPC, KIAA1429, METTL14, METTL3, WTAP, is opposite to its CNV alterations. For example, HNRNPC and METTL3 with CNV deletion in GBM tissue have a relatively higher transcriptome expression level than that in tumor tissue. These opposite trends could be attributed to transcriptional events mediated by transcriptional factors and epigenetic changes like histone modifications, DNA methylations, which need to be further elucidated in GBM progression. Adapting R package ConsensusClusterPlus, we divided 495 GBM patients into two clusters with distinct m6A modification patterns according to transcriptome expression levels of 21 m6A regulators (Supplemental Figures 2A–C). In addition, the heatmap of 21 m6A regulators, classified by the abovementioned two clusters, demonstrates the relationship between expression level and matching clinical information, including age, clinical status, CIMP, and histology subgroup. Notably, GBM patients in m6A cluster B are more likely to express CIMP. Regarding the histology subgroup GBM patients in m6A cluster A tend to be in
classical and mesenchymal subtype while patients in m^6^A cluster B tend to be in Neural and Proneuronal subtype. And there is no significant difference in the age distribution between two m^6^A clusters (Figure 2C). PCA analysis according to transcriptional expression level of m^6^A regulators also completely distinguished between two clusters, implying two m^6^A clusters exist distinct expression profiles of m^6^A regulators (Figure 2D). Regulators in the same functional module tend to express similarly. Besides, there is also a significant correlation between methyltransferases and demethylases. For example,
among subgroups with higher expression levels of eraser ALKBH5, most writers express the same trend, including METTL14, RBM15, RBM15B, WTAP, CBLL1, and ZC3H13 (Figure 3A). Simultaneously, regarding samples with higher expression of FTO (another eraser), we observe a significantly higher level of writers, implying that writers and erasers display a potential interactive effect (Figure 3B). In total, 2 m6A clusters with potentially different m6A modification pattern were determined within the 495 GBM patients based on the transcriptome expression level of 21 m6A regulators. m6A cluster A was characterized by the relatively low expression of FTO, KIAA1429, ZC3H13, FMR1, LRPPRC, IGFBP1,
YTHDC1 and high expression of the remaining regulators, while m^6^A cluster B showed an opposite trend. Although no significant difference in the age distribution was identified, other corresponding clinical information including CIMP and histology subgroup expressed distinct between 2 m^6^A clusters, indicating that 2 m^6^A clusters with different expression pattern of 21 regulators could have potential mechanisms to mediate these adverse clinical features.

**FIGURE 3** | The relationship between m^6^A modification genes and specific immune cell infiltration. (A) The expression level of eraser ALKBH5 between high and low expression groups of writers, including METTL3/14, RBM 15/15B, WTAP, KIAA1429, CBLL1, and ZC3H13. (B) The same as A in eraser FTO. (C) Correlation between 23 immune cells infiltration level and 21 m^6^A modification regulators. (D) The enrichment level of immune related pathways in KEGG between high and low expression groups of ELAVL1. (E, F) The response percentage for PD-L1 treatment in high and low expression groups of ELAVL1. SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response.
**Immune Cell Infiltration Features in Different m\textsuperscript{6}A Modification Modules**

Spearman correlation of infiltration levels between 23 immune cells and 21 m\textsuperscript{6}A regulators demonstrated that expression level of m\textsuperscript{6}A regulators and TME infiltration closely related to each other. It is suggested that clarifying expression modes of m\textsuperscript{6}A regulators is of great significance for forecasting anticancer immune responses, which could be a powerful tool to indicate the efficacy of immunotherapies, such as PD-L1 treatment in GBM patients (Figure 3C). We also found that the expression level of the regulator ELAVL1 negatively correlated with the infiltration level of most immune cells, except only type 2 T helper cells and activated CD4+ T cells. Utilizing GSVA to compare immune-related KEGG pathway enrichment degree between subgroups expressing high and low ELAVL1 levels, it was demonstrated that subgroups with high ELAVL1 expression tend to exhibit relatively low enrichment degrees in immune-related pathways and vice versa (Figure 3D). Besides, infiltration levels of 23 immune cells and the difference in expression of MHC molecules, costimulatory molecules, and adhesion molecules among subgroups with high and low ELAVL1 expression showed the same trend: the expression of ELAVL1 is negatively correlated to the infiltration level of most immune cells and above-mentioned immune-related modules (Supplemental Figures 3A, B).

The results indicate that m\textsuperscript{6}A regulator ELAVL1 is a potential predictive factor of immune response, which could be applied to forecasting the anticancer efficacy of immunotherapy. To elucidate the relationship between expression level of ELAVL1 and response to immunotherapy, we included a urothelial cancer cohort treated with anti-PD-L1 antibody (40). The Kaplan-Meier survival curve between two groups classified by ELAVL1 expression did not differ significantly ($p$-value = 0.38, Supplemental Figure 3C). In addition, Figures 3E, F demonstrate the proportion of patients with response to PD-L1 blockade immunotherapy in low or high ELAVL1 groups, indicating that high ELAVL1 expression correlates with relative efficient responses to PD-L1 treatment. KEGG and GO enrichment analysis for DEGs obtained from two clusters with distinct m\textsuperscript{6}A modification patterns indicates that several immune-related KEGG pathways and GO annotation are significantly upregulated, such as neutrophil-mediated immunity and neutrophil activation involved in immune responses, which also supports the results indicating that m\textsuperscript{6}A modification patterns are closely correlated to immune response (Figures 4A, B).

**Establishment and Validation of m\textsuperscript{6}A Methylation-Based Prognostic Assessment Pipeline (MPAP)**

To further explore the potential prognostic value of m\textsuperscript{6}A methylation modifications, we constructed the MPAP, which could be used to assess GBM patients’ prognosis. Using DEGs obtained from two clusters with different m\textsuperscript{6}A modification patterns for Robustness regression, we chose the optimum Cox modeling gene for the construction of our pipeline. Thereafter, LASSO regression was applied for the establishment of the MPAP, during which 13 genes and the correlation coefficients were obtained (Supplemental Figures 4A, B). According to the expression value of 13 genes and the correlation coefficients, we computed the m\textsuperscript{6}A modification score to divide GBM patients into groups with distinct clinical outcomes (Figure 4D). The overall survival of the high-risk m\textsuperscript{6}A modification group is significantly shorter than that of the low-risk group with a log-ranked $p$-value < 0.0001. The expression levels of 13 genes (AEBP1, ARL4C, ASL, CHST2, FKBP9, GPI, GYS1, IGFBP2, LDHA, LGALS3, SLC2A10, TSTD1, YKT6) are depicted in the heatmap (Figure 4C).

Simultaneously, for the purpose of testing the robustness of the MPAP, we utilized another GBM cohort from CGGA for prognostic prediction as a validation dataset. Similarly, GBM patients in the validation set were divided into two m\textsuperscript{6}A modification pattern-based risk groups according to MMS obtained using the MPAP. The expression levels of 13 genes are also depicted in the heatmap (Figure 4F). The Kaplan-Meier curve depicted by matching clinical outcomes reveals a similar trend: the overall survival of the high-risk m\textsuperscript{6}A modification group is significantly shorter than that of the low-risk group (log-ranked $p$-value = 0.00036), which confirms the robustness of our model in a different GBM cohort (Figure 4G).

Furthermore, we depicted ROC curves of the predictive model in the training and validation sets. The MPAP displays satisfactory prediction sensitivity and specificity with the area under the ROC curve measuring 0.720 and 0.622 in the training and validation sets, respectively (Figures 4E, H). The multivariate Cox regression analysis confirmed that the MPAP was an independent prognostic predictor in GBM patients with a log-ranked $p$-value <0.001 (Figure 5A), and the same result was obtained in the validation set (Figure 5B). To reveal the correlation between 21 m\textsuperscript{6}A regulators and 13 signatures in the MPAP, we depicted a network diagram indicating that most regulators and signatures are regulated positively by each other, except TSTD1 and KIAA1429 (Figure 6A). In addition, a nomogram was established to quantitatively forecast the clinical outcomes matching other clinical predictors, which indicates that the MMS was the most valuable predictor (Figure 6B). The calibration plot simultaneously demonstrated superior clinical predictive efficiency (Figure 6C). In ROC curve, area under the curve (AUC) at 1 year, 3 year and 5 year were 0.704, 0.803 and 0.87 respectively, which indicates that the nomogram have a superior sensitivity and specificity in predicting the probability of survival (Figure 6D).

**DISCUSSION**

GBM is a group of heterogeneous intracranial neoplasms with distinct histopathological and molecular biological characteristics, resulting in different subsets of patients benefitting from various treatment strategies, despite advancement in multiple therapies for malignant gliomas, including checkpoint inhibitors and targeted therapies et al. (6, 43, 44). To solve this problem, it is urgent to...
FIGURE 4 | Signature patterns of expression level and biological characteristics of each risk group separated by MPAP. (A, B) Bubble plots showing the GO and KEGG annotation of DEGs obtained from two m6A modification clusters. (C, D) Heatmaps demonstrating the expression level of 13 m6A related signatures and the matched clinical information in the training dataset and validation dataset. (E, F) Kaplan-Meier survival curves of risk groups separated by MPAP in the training dataset and validation dataset. (G, H) ROC curves of the MPAP in the training set and validation set.
To establish a risk stratification method and classify GBM patients into various risk groups with diverse anticancer responses to various therapies. Although the classical approach for identifying specific targets and assessing prognosis has made remarkable achievements, such as immunohistochemistry (IHC) and traditional histopathology, we require more comprehensive and thorough tools to adapt the changing treatment strategies. Despite its powerful efficiency in detecting potential therapeutic targets and eliminating interference of intra-tumoral heterogeneity, scRNA-seq cannot be applied to clinical settings due to the high costs of sequencing and is thus only used for laboratory research. Recently, many studies have suggested that m^6^A methylation modification influences multiple processes during cancer progression, such as inflammation and specific cellular signaling pathways (45). Therefore, applying next generation sequencing (NGS) to explore m^6^A methylation modification patterns in GBM will contribute to the classification of GBM patients for precision medicine and individualized treatment.

Recently, mRNA m^6^A methylation modification was reported to have significant role in multiple immune-related biological processes. 

**FIGURE 5** The multivariate Cox regression analysis depicts log-ranked p-values of each factor to predict the prognosis in the training dataset and validation dataset. (A) The forest plot shows the results of multivariate Cox regression analysis in the training dataset, in which the black squares represent the Hazard Ratio (HR) and the whiskers around the squares represent the 95% confidence interval. The figures on the left side are the HR of each predictor while on the right side are the p-value. (B) The same as A in the validation dataset. AIC, Akaike information criterion.
process including innate and adaptive immune response, immune cell homeostasis, immune recognition as well as anti-tumor immunity (14, 46–48). Although various evidence suggested single m6A regulator is related to individual type of immune cell and specific aspect of immunity (48), integrated analysis of 21 m6A regulators to determine its relationship with multiple immune cell infiltration has not been conducted in GBM. Since substantial evidence demonstrated that some mutational signature can be utilized to predict a poor T cell infiltration, low survival rate and multiple systematic therapy resistance in gliomas especially for PD-1 blockade (49), comprehensive recognition of epigenetic modification mediated...
immune cell infiltration feature in intracranial malignancies can provide novel insights into risk stratification and clinical therapeutic strategy. Hence, we identified 2 diverse m6A methylation modification patterns in GBM patients with distinct tumor microenvironment immune cell infiltration utilizing 21 m6A modification regulators. However, the concrete mechanism regarding how regulators influence immune cell infiltration and proceed to regulator immune responses requires further clarification. In addition, it is important to elucidate the interaction and mechanism among m6A regulators and to find hub regulators that could be adopted for GBM treatment. Our research provides practical ideas for the above-mentioned challenges. However, further research is required to understand how m6A modification affects immune response.

Increasing evidence suggested that m6A modification play an extensive role in antitumoral drug resistance through various mechanisms including drug transport and metabolism, mutational drug targets, cellular damage repair etc (50). It was also reported that targeting some specific m6A regulators can substantially surmount drug resistance in several cancers (51–53). Notably, previous study demonstrated that methylation modification of MGMT promoter can lead to increased chemotherapeutic effect in high grade gliomas (54, 55). Therefore, identifying epigenetic modification related targets will contribute to enhancing anticancer effect of systematic treatment in GBM especially of immunotherapy. And integration of multiple therapy and choosing the optimum treatment strategy on the basis of advanced risk stratification model may be the future direction for treating intracranial malignancies. It was also confirmed that DEGs obtained from differential expression analysis between two clusters with different m6A methylation modification modes were closely related to epigenetic and immune response-related KEGG pathways and GO terms, for example, neutrophil-mediated immunity and neutrophil activation involved in immune responses. We considered these m6A modification related DEGs as key signature genes in GBM, which could be utilized to detect potential characteristics within intra-tumoral heterogeneity of GBM, including immune cell infiltration. Thus, using these m6A modification-related signature genes, the MPAP was constructed to quantitatively assess m6A patterns in GBM. Hence the MPAP could be used as a novel tool to relatively assess GBM patients’ prognosis and guide clinical decision-making. As the means of GBM therapy diversifies, formulating treatment strategy based on prognostic models to guide precision medicine will be a trend in the fields of cancer treatment (56, 57).

However, our study has a few limitations: retrospective research displays statistical bias and the traditional bulk sequence transcriptome data lack comprehensive exploration for the intra-tumoral heterogeneity. Admittedly, there is urgent demand for a prospective study to acquire a superior fit. Yet, we have established a superior predictive model to quantitatively assess GBM patients’ clinical outcomes based on m6A modifications through multiple transcriptome data, at a relatively low price that could be widely used.

Additionally, although recent study had explored the connection between tumor mutational burden and immunotherapy response in gliomas (49), the influence of specific gene for the efficacy of immunotherapy in GBM has not been elucidated due to the small sample capacity in the research on the effect of immunotherapy for GBM. Instead, we applied a urothelial cancer cohort treated by PD-L1 blockade to explore the connection between transcriptome expression pattern and immunotherapy response and ELAVL1 was determined to be a predictor for the efficacy of PD-L1 blockade. But that urothelial cancer cohort is different from GBM in some respects, for example, tumor samples in that cohort are metastases. And urothelial cancer is thought to be in a totally different immune subtype from GBM (58), which will affect the prediction value of ELAVL1 on immunotherapy. To clarify these confusions, we further explore the correlation between the expression level of 21 m6A regulators and immune cells infiltration level in that urothelial cancer cohort (Supplemental Figure 5). It was demonstrated that the correlation between ELAVL1 and 23 immune cells infiltration level in the urothelial cancer has a similar trend with that in GBM cohort (Supplemental Figure 5, Figure 3C), which support our conclusion to a certain extent. However, due to the heterogeneity between urothelial cancer and GBM the prediction value of ELAVL1 and its potential mechanism for immunotherapy still needs to be further proved by large glioma cohort treated by PD-1/L1 blockade.

To summarize, comprehensively studying the m6A methylation modification patterns in GBM patients, two diverse m6A phenotypes with distinct epigenetic modification modes were identified to explore m6A modification-related signatures. Using a quantitative method to assess the infiltration level of 23 immune cells in transcriptome expression data, we integrated these m6A regulated signature genes for further analysis to determine the relationship between immune responses and m6A modifications, which we could apply to estimate anticancer responses to immunotherapies in clinical practice. According to our results, m6A modification regulator ELAVL1 was identified to potentially play a role in the efficient prediction of PD-L1 treatment, while the effect of other m6A regulators on specific treatment strategies were to be determined. Considering the urgent demand for the construction of a risk stratification and prognosis assessment system in GBM patients to cautiously formulate treatment management, we established the MPAP using the m6A-related signature genes to assess the m6A modification level, by which immune cell infiltration level can be identified and then be used to predict the clinical outcomes for patients receiving immunotherapy treatment. Furthermore, integrating other clinical information, including CIMP and age, we constructed a nomogram to precisely forecast GBM patients’ survival time, in which the MMS obtained from MPAP was the leading predictor. In short, our findings provided a comprehensive understanding of m6A modifications in GBM and provided a powerful, high quality tool at a low cost to quantitatively estimate GBM patients’ therapeutic response and clinical prognosis.
CONCLUSIONS

In conclusion, by detecting distinct expression patterns of 21 m^6A modification regulators in GBM, this study successfully identified 13 m^6A-related signatures and constructed the MPAP combining the Robust and LASSO regression, which we could employ to quantitatively predict the prognosis of GBM patients. Additionally, we also determined that m^6A regulators are correlated with specific immune cell infiltration levels. Comprehensively exploring m^6A modification patterns in GBM will enhance our understanding of immune infiltration features in order to better manage the treatment strategies and improve clinical outcomes.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. These data can be found here: https://xena.ucsc.edu https://gliovis.bioinfo.cnio.es.

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

YP and KX wrote the manuscript and drew the figures. YL and YZL collected the data. QL wrote the manuscript and supervised the entire project. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. *Neuro Oncol* (2018) 20 (suppl_4):v1–v86. doi: 10.1093/neuonc/not131
2. Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. *JAMA Oncol* (2018) 4(9):1254–62. doi: 10.1001/jamaoncol.2018.1789
3. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. *Neuro Oncol* (2013) 15 Suppl 2 (Suppl 2):ii1–56. doi: 10.1093/neuonc/not151
4. Taphoorn MJ, Sizoo EM, Bottomley A. Review on quality of life issues in patients with primary brain tumors. *Oncologist* (2010) 15(6):618–26. doi: 10.1634/theoncologist.2009-0291
5. Pinel S, Thomas N, Bourz C, Barbieri-Heyob M. Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment. *Adv Drug Deliv Rev* (2019) 138:344–57. doi: 10.1016/j.addr.2018.10.013
6. Lapointe S, Perry A, Butowsky N.A. Primary brain tumours in adults. *Lancet* (2018) 392(10145):432–46. doi: 10.1016/s0140-6736(18)30990-5
7. Huang J, Liu F, Liu Z, Tang H, Wu H, Gong Q, et al. Immune Checkpoint in Glioblastoma: Promising and Challenging. *Front Pharmacol* (2017) 8:242. doi: 10.3389/fphar.2017.00242
8. Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, et al. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. *J Clin Oncol* (2018) 36(14):1419–27. doi: 10.1200/jco.2017.75.8219
9. De Felice F, Pramno N, Marampon F, Musio D, Salducci M, Polimeni A, et al. Immune check-point in glioblastoma multiforme. *Crit Rev Oncol Hematol* (2019) 138:60–9. doi: 10.1016/j.critrevonc.2019.03.019
10. Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. *Clin Cancer Res* (2019) 25(4):4202–10. doi: 10.1158/1078-0432.Ccr-18-1627
11. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DR, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nat Med* (2018) 24(5):541–50. doi: 10.1038/s41591-018-0014-x
12. Ali HR, Chlon L, Pharoah PD, Markowitz F, Caldas C. Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. *PLoS Med* (2016) 13(12):e1002194. doi: 10.1371/journal.pmed.1002194
13. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. *Nat Med* (2013) 19(11):1423–37. doi: 10.1038/nm.3394
14. Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in

FUNDING

This work was supported by the National Natural Science Foundation of China (grant number 81802974)

ACKNOWLEDGMENTS

All contributors to this study are included in the list of authors.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.632934/full#supplementary-material

Supplementary Figure 1 | Principle component analysis (PCA) of m6A modification genes to differentiate normal and tumor tissue.

Supplementary Figure 2 | Consensus clustering of GBM patients’ m6A modification regulators. (A) Consensus matrices of the GBM cohort for k (number of clusters) = 2 dividing GBM patients into two clusters. (B) Empirical cumulative distribution function (CDF) plot display consensus distributions for each k, which suggests dividing the patients into 2 groups reach the maximum stability. (C) The relative change area under CDF curve (y-axis) indicates the relative increase in cluster stability, which means the optimal k=2.

Supplementary Figure 3 | (A) infiltration level of 23 immune cells between groups with high and low ELAVL1. (B) Expression level of MHC molecules, co-stimulatory molecules, and adhesion molecule between groups with high and low ELAVL1. (C) Kaplan-Meier survival curves of groups with high and low ELAVL1 expression level.

Supplementary Figure 4 | (A) LASSO coefficient profiles of the m6A related signatures. (B) Using 10-fold cross-validation to the optimal penalty parameter lambda.

Supplementary Figure 5 | Correlation between 23 immune cells infiltration level and 21 m6A modification regulators.
36. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. A gene-expression-based method for comparing biological themes among gene clusters. *Oncogene* (2012) 16(5):284–7. doi: 10.1038/omi.2011.0118

37. Hanelmann S, Castelo R, Guinney J. GSA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinf* (2013) 14:7. doi: 10.1186/1471-2105-14-7

38. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. *Onciss* (2012) 16(5):284–7. doi: 10.1038/omi.2011.0118

39. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* (2015) 43(7):e47. doi: 10.1093/nar/gkv007

40. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature* (2018) 554(7693):544–8. doi: 10.1038/ nature25501

41. Peng D, Wang L, Li H, Cai C, Tan Y, Xu B, et al. An immune infiltration signature to predict the overall survival of patients with colon cancer. *JURMB* (2019) 71(1):760–70. doi: 10.1002/jub.2124

42. Tian MX, Liu WR, Wang H, Zhou YF, Jin L, Jiang XF, et al. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. *BMC Med* (2019) 17(1):106. doi: 10.1038/s12916-019-1341-6

43. Zhu GQ, Zhou YJ, Qiu LX, Wang B, Yang Y, Liao WT, et al. Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data. *Carcinogenesis* (2019) 40:1077–85. doi: 10.1038/s41467-019-02685-7

44. Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. *Mol Cancer* (2017) 16(1):100. doi: 10.1186/s12943-017-0670-3

45. Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. mL6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. *Mol Cancer* (2020) 19(1):53. doi: 10.1038/s41590-020-0650-4

46. Li HB, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, et al. mL6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathway. *Nature* (2019) 548(7676):338–42. doi: 10.1038/nature23450

47. Winkler R, Gillis E, Lasman L, Safra M, Geula S, Soyris C, et al. mL6A modification controls the innate immune response to infection by targeting type I interferons. *Nat Immunol* (2019) 20(2):173–82. doi: 10.1038/s41590-018-0275-z

48. Shulman Z, Stern-Ginossar N. The RNA modification N(6)-methyladenosine as a novel regulator of the immune system. *Nat Immunol* (2020) 21(5):501–12. doi: 10.1038/s41590-020-0650-4

49. Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. *Nature* (2020) 580(7784):517–23. doi: 10.1038/s41586-2020-2209-9

50. Li B, Jiang J, Assaraf YG, Xiao H, Chen ZS, Huang C. Surmounting cancer drug resistance: New insights from the perspective of N(6)-methyladenosine RNA modification. *Drug Resist Update* (2020) 53:100720. doi: 10.1016/j.drup.2020.100720

51. Yan F, Al-Kali A, Zhang Z, Liu J, Pang J, Zhao N, et al. Dynamic N(6)-methyladenosine methylation regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. *Cell Res* (2018) 28(11):1062–76. doi: 10.1038/s41422-018-0097-4

52. Huang H, Wang H, Chen J. mL6A modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. *Cancer Cell* (2020) 37(3):270–88. doi: 10.1016/j.ccell.2020.02.004

53. Meng Q, Wang S, Zhou S, Liu H, Ma X, Zhou X, et al. Dissecting the mL6A methylation affection on afatinib resistance in non-small cell lung cancer. *Pharmacogenomics J* (2020) 20(2):227–34. doi: 10.1007/s12943-019-0110-4

54. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and temozolomide benefit in glioblastoma. *N Engl J Med* (2005) 352(10):997–1003. doi: 10.1056/NEJMoa043331

55. Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. *Nat Rev Genet* (2019) 20(2):109–27. doi: 10.1038/s41576-018-0074-2
56. Kennedy BC, Showers CR, Anderson DE, Anderson L, Canoll P, Bruce JN, et al. Tumor-associated macrophages in glioma: friend or foe? *J Oncol* (2013) 2013:486912. doi: 10.1155/2013/486912

57. Vidyarthi A, Agnihotri T, Khan N, Singh S, Tewari MK, Radotra BD, et al. Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity. *Cancer Immunol Immunother* (2019) 68(12):1995–2004. doi: 10.1007/s00262-019-02423-8

58. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The Immune Landscape of Cancer. *Immunity* (2018) 48(4):812–30.e14. doi: 10.1016/j.immuni.2018.03.023

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 Pan, Xiao, Li, Li and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*